Global Pulmonary Arterial Hypertension Market is valued at USD 7.89 Billion in 2021 and is expected to reach USD 12.28 Billion by 2028 with a CAGR of 6.5% over the forecast period. Increasing geriatric population, rising prevalence of pulmonary arterial hypertension, and a growing number of supportive government initiatives are some of the major factors driving the growth of the Global Pulmonary Arterial Hypertension Market.
Scope of Global Pulmonary Arterial Hypertension Market Report:-
Pulmonary arterial hypertension (PAH) is a rare disease that affects the pulmonary arteries. It is characterized by narrow and blocked arteries and capillaries. Having pulmonary arterial hypertension (PAH) implies that have hypertension in the arteries that go from your heart to lungs. It's not the same as having normal high blood pressure. With pulmonary arterial hypertension, the minuscule arteries in lungs become thin or blocked. It's harder for blood to flow throughout them, and that brings the pulse up in your lungs. Heart needs to work harder to pump blood through those arteries, and inevitably the heart muscle gets weak. Under adverse conditions, it can also compromise the heart's ability to pump blood, leading to eventual heart failure. PAH is characterized by shortness of breath, fatigue, and swelling of the ankles and feet. It is diagnosed by various tests such as an echocardiogram, computer tomography (CT) scan, chest X-ray, and ventilation-perfusion scan.
The effect of Covid outbreak on the business peaked during mid 2020 wherein, pulmonary arterial hypertension patients were at a higher risk of experiencing Covid. Different difficulties remembering obstruction for diagnostic testing, changed rules relating to the hospital & emergency care, and hindered drug production network among others blocked the business development during the pandemic. The pandemic has shown the significance of PAH drugs as a reaction to the rising number of hospitalized PAH-COVID-19 patients.
2018 - 2021
2022 - 2028
Market Size in 2021:
USD 7.89 Billion
Base year considered
Forecast Period CAGR %:
Market Size Expected in 2028:
USD 12.28 Billion
Tables, Charts & Figures:
Pulmonary Arterial Hypertension Companies
United Therapeutics Corporation, Lupin Pharmaceuticals, Inc., Gilead Sciences, Inc., Bayer, Johnson & Johnson, GlaxoSmithKline, Sandoz Inc. (Novartis), Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., and others.
By Drug Class, By Type, By Route of Administration
North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
Global Pulmonary Arterial Hypertension Market Segmentation:-
The global pulmonary arterial hypertension market is segmented on the basis of the drug class, type, route of administration, and region & country level. On the basis of drug class, the global pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), SGC stimulators, and PDE-5 inhibitors. By type, the market is segmented into generics and branded. By route of administration, the global pulmonary arterial hypertension market is segmented into oral, inhalational, and intravenous/ subcutaneous.
By Drug Class
By Route of Administration:
Pulmonary Arterial Hypertension Market Key Players
The major players included in the global Pulmonary Arterial Hypertension market forecast are,
News- Bayer Launched KSA’s First Digital Platform for Pulmonary Hypertension Management
On February 23rd, 2022; Bayer launched Saudi Arabia's first ""digital hub"" to improve the management of pulmonary hypertension (PH). The AAN Digital Hub designed to bridge the gap between the diagnosis and treatment of the condition during covid-19 epidemic focuses on facilitating virtual referrals for patients, as well as enabling the exchange of knowledge between primary care physicians and specialists and their patients.
Aerovate Launched a Clinical Trial of AV-101 in Pulmonary Arterial Hypertension
On December 17th, 2021; Aerovate Therapeutics started a Phase 2b/3 clinical preliminary that will test AV-101, the organizations exploratory breathed formulation of imatinib, in individuals with pulmonary arterial hypertension (PAH). The primary objective of the Phase 2b piece is to decide the impact on pulmonary arterial hypertension (PVR) — protection from blood stream in the lungs' veins — following 24 weeks, or around a half year. Security, decency, and other clinical measures additionally will be surveyed. The test, called IMPAHCT (NCT05036135), is presently enrolling participants at the University of Kansas Medical Center in Kansas City, Kansas, with additional sites planned to open later.
Increasing Geriatric Population, Rising Prevalence of Pulmonary Arterial Hypertension, and Growing Technological Advancement are Some of the Major Factors Driving the Market Growth
One of the major factors driving the growth of the pulmonary arterial hypertension market is the increasing geriatric population. For example, as per the United Nation, in 2019, there were 703 million people aged 65 in the globe. The number of geriatric people is projected to double to 1.5 billion by 2050. Thus, at a significant rate of population aging, the frequency of PAHs in the aging population will increase in the near future. Pulmonary arterial hypertension mainly occurs in patients over 60 years of age, which is considered to be related to the maturation process. The maturing lung is reliant upon natural changes which make it extra susceptible to infection. Due to this demographic change, the number and proportion of more than 60 people have increased. With the huge extent of populace aging, the frequency of PAH in the old populace will increment soon. Rising age is one of the non-modifiable variables that floods the risk connected with PAH. Also, the older populace base is inclined to this sickness because of diastolic dysfunction and age-related blood vessel hardening that further increases the business demand.
In addition, the rising prevalence of pulmonary arterial hypertension is also boosting the market growth owing to the causative diseases including lung diseases, human immunodeficiency virus (HIV) connected tissue disorders, chronic liver diseases, and other conditions. Additionally, rising adoption of the inactive lifestyle, increasing consumption of alcohol, and growing smoking occurrence between adults are factors presenting a large patient pool suffering from pulmonary arterial hypertension worldwide. For instance; according to American Lung Association; on October 23rd, 2020; about 500-1000 new cases were diagnosed each year in the US. About 15-20% of patients with pulmonary arterial hypertension have inherited the condition.
Moreover, the growing number of supportive government initiatives are also fostering the market growth. Governments of different nations across the globe are giving funds for the development and distribution of high-quality therapies for the treatment of this condition. Also, the flare-up of the Covid-19 pandemic is probably going to drive the development in this market. Covid-19 can frequently prompt cardiovascular and pulmonary complications. Different clinical research studies based SARS-CoV-2 displayed that the infection is fit for changing the pulmonary hemodynamic through the components of venous thromboembolism, thrombotic microangiopathy, endothelial brokenness, and vascular hole. For example, in January 2021, the National Center for Biotechnology Information (NCBI) distributed a review which expresses that those patients who passed on from Covid-19, showed thickened pulmonary vascular walls. This demonstrates the way that in future, SARS-CoV-2 can set off the high susceptibility of contaminated people to developing pulmonary arterial hypertension.
However, side effects related with PAH drugs may hamper the growth of the global pulmonary arterial hypertension market. In spite of that, the growing advancements in this field may offer an opportunity for the further growth of the market.
North America is Expected to Dominate the Global Pulmonary Arterial Hypertension Market
Geographically, North America is expected to dominate the global pulmonary arterial hypertension market within the forecast period due to the increasing prevalence of pulmonary arterial hypertension, rising cases of cardiovascular diseases, and presence of key players this region. The increasing prevalence of pulmonary arterial hypertension is increasing in the country attributed to the risk factors comprising smoking, HIV, alcohol consumption, and a sedentary lifestyle, among others. For instance; according to American Lung Association, on October 23rd, 2020; about 500-1000 new cases are diagnosed each year in the U.S. About 15-20% of patients with pulmonary arterial hypertension have inherited the condition. The increasing prevalence of cardiovascular diseases combined with the rising number of regulatory approvals being granted to new treatment medications are also fostering the market growth in this region. For instance; according to Cleveland Clinic, on May 5th, 2022; about 18 million people died of cardiovascular diseases in the US. Cardiovascular diseases are more likely to suffer from pulmonary arterial hypertension which is likely to boost the market growth.
Europe is expected to show significant growth in the global pulmonary arterial hypertension market due to the rising geriatric population, and growing technological advancements in this region. For instance; as per the news published, on February 23rd, 2022; Bayer launched KSA’s first digital platform for pulmonary hypertension management.
On Special Pulmonary Pulmonary Arterial Hypertension Market Report is also available for the below Regions and Countries:
The Middle East and Africa
Key Benefits of Global Pulmonary Arterial Hypertension Market Report–
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®